{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-26-000081","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2026-06-18T12:01:46+00:00","discovered_at":"2026-06-18T12:05:00.232041+00:00","generated_at":"2026-06-18T12:05:17.590832+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Denali sells Rare Pediatric Disease PRV for $195M to fund pipeline","bullets":["Gross proceeds of $195M from sale of PRV awarded after FDA approval of AVLAYAH for Hunter syndrome in March 2026.","Proceeds to advance clinical pipeline including DNL126 (MPS IIIA), DNL593 (FTD), DNL952 (Pompe), DNL628 (Alzheimer's).","Transaction subject to HSR waiting period; expected to close after customary conditions.","Denali's TV platform enabled AVLAYAH, first FDA-approved biologic to cross blood-brain barrier via transferrin receptor."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-26-000081","json":"https://secwatch.observer/filing/0001714899-26-000081.json","markdown":"https://secwatch.observer/filing/0001714899-26-000081.md","text":"https://secwatch.observer/filing/0001714899-26-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/0001714899-26-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/dnli-20260612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:05:17.590832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"481ceb4499cb299edceb288bc2f5c2fae5b82e58","claim":"Denali Therapeutics Inc. entered into PRV Transfer Agreement valued at $195 million (effective 2026-06-12).","evidence_excerpt":"On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/0001714899-26-000081-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Value","value":"$195 million"},{"label":"Effective","value":"2026-06-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}